Iressa in the treatment of Brain Metastases from Non Small Cell Lung Cancer
Study identifier:1839IL/0569
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Terminated/Withdrawn
Official Title
A Phase II, Multicentre, Non-Comparative, Open-Label Study To Evaluate The Efficacy And Tolerability Of ZD1839 (Iressa™) In Asymptomatic Radio-Naive Patients With Brain Metastases From Non-Small Cell Lung Carcinoma (NSCLC) Who Have Relapsed Following Prior Chemotherapy
Medical condition
Brain Neoplasms
Phase
Phase 2
Healthy volunteers
No
Study drug
Iressa (Gefitinib)
Sex
All
Actual Enrollment
47
Study type
Interventional
Age
18 Years +
Date
Study Start Date: 01 Jul 2004
Primary Completion Date: -
Study Completion Date: -
Study design
Allocation: Non-randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Verification:
Verified 01 Jun 2009 by AstraZeneca Pharmaceuticals
Sponsors
AstraZeneca Pharmaceuticals
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|
Contacts
Investigators
Principal Investigator
Lucio Crino
Bologna, Italy
